

Barcelona, November 1th 2021

OTHER RELEVANT INFORMATION

AstraZeneca to transfer global rights for Eklira and Duaklir to Covis Pharma

In accordance with Securities Markets Law, Almirall, S.A. ("Almirall") announces the following:

AstraZeneca has agreed to transfer its global rights to *Eklira* (aclidinium bromide), known as *Tudorza* in the US, and *Duaklir* (aclidinium bromide/formoterol) to Covis Pharma Group (Covis Pharma).

Both medicines are delivered via the *Genuair* device and used for the treatment of patients with chronic obstructive pulmonary disease (COPD).

Almirall will continue to receive Milestones and Royalties from the agreement initially signed with AstraZeneca.

The agreement will ensure continued patient access to these established medicines.

Yours sincerely,

Pablo Divasson del Fraile
Investor Relations Department
investors@almirall.com